IDEAYA Biosciences, Inc.

IDEAYA Biosciences is a clinical-stage precision oncology company focused on discovering and developing targeted cancer therapies matched to specific molecular alterations. Its pipeline centers on small-molecule programs, synthetic lethality, and antibody-drug conjugates, with development guided by companion diagnostics and biomarker selection.

−71,6 %

−52,0 %

+3 024,4 %

11.34

11.34

— IDEAYA Biosciences, Inc.
%
Darovasertib / uveal melanoma10% Clinical development of darovasertib for uveal melanoma, including combination and registrational studies.
ADC and DDR combinations25% Antibody-drug conjugate and DNA damage response combination programs in molecularly defined solid tumors.
MTAP pathway programs20% Targeted therapies aimed at MTAP-deleted cancers and related synthetic lethality biology.
Next-generation therapies20% Earlier-stage discovery and development programs beyond the current lead assets.
Collaboration revenue and diagnostics enablement25% Revenue from partnered R&D, licensing, milestones, and diagnostic-enabling activities.

IDEAYA does not yet sell approved products; its current counterparties are pharmaceutical partners, diagnostic...

  • Pharmaceutical collaboration partnersprimary

    Partners such as GSK, Servier, Pfizer, Gilead, Biocytogen, and Hengrui support development, licensing, supply, or commercialization of specific programs.

  • Diagnostic and biomarker partnersprimary

    Companies like Foundation Medicine, Guardant Health, and Tempus help identify patients most likely to benefit from IDEAYA's therapies.

  • Clinical investigators and trial sitesprimary

    Academic and community oncology centers enroll patients into biomarker-selected studies and registrational trials.

  • Future oncology prescriberssecondary

    Specialist oncologists would prescribe approved products for defined cancer subtypes if the pipeline reaches commercialization.

  • Contract manufacturing organizationssecondary

    CMOs manufacture API, drug product, and related supply for preclinical, clinical, and future commercial use.

IDEAYA is headquartered in the United States and currently expects to commercialize any approved medicines first in the...

  • •United States is the planned first commercial market
  • •Europe is a potential expansion market for future products
  • •Servier holds ex-U.S. rights to darovasertib worldwide
  • •Clinical and diagnostic partners are globally distributed
  • •Manufacturing is outsourced to third-party CMOs

IDEAYA's strategy is to build a precision oncology pipeline around molecularly defined cancers where biomarker...

01
Advance darovasertib in uveal melanomashort-term

This is the most advanced asset and a potential first commercial product.

02
Progress ADC, DDR, and MTAP pipeline programsmedium-term

Diversifies the pipeline and creates multiple shots on goal in precision oncology.

03
Expand biomarker and diagnostic capabilitiesmedium-term

Patient selection is central to the company's precision-medicine thesis and trial success.

04
Use partnerships for ex-U.S. commercialization and fundingshort-term

Partnerships reduce capital needs and provide external validation for programs.

IDEAYA is a clinical-stage biotech with no approved products, so its value depends on successful trials, regulatory...

high

Clinical development failure

Pipeline value depends on demonstrating safety and efficacy in biomarker-defined cancers.

Scope
Darovasertib, ADC/DDR, MTAP, and next-generation programs
Materiality
high
high

Financing risk

The company has significant losses and will likely need additional capital to fund development.

Scope
Equity issuance, collaborations, or debt financing
Materiality
high
medium

Competition from larger oncology companies

Rivals may develop similar targeted therapies faster or with greater resources.

Scope
Targeted oncology, synthetic lethality, and ADC markets
Materiality
high
medium

Commercialization and reimbursement risk

Even approved products may face payer resistance or limited reimbursement in niche indications.

Scope
U.S. launch and future ex-U.S. markets
Materiality
medium
medium

Manufacturing and supply-chain dependence

The company relies on third-party CMOs for API, drug product, and diagnostics supply.

Scope
Clinical and future commercial supply
Materiality
medium
Collaboration revenue recognition
Can cause large quarter-to-quarter swings in reported revenue
Contract assets and liabilities
Affects balance sheet presentation and revenue timing
Stock-based compensation
Impacts reported losses and non-cash expense trends
Marketable securities valuation
Fair value changes can affect other comprehensive income and liquidity disclosure

Aldeyra Therapeutics, Inc.

ALDX · Pharmaceutical Preparations

Tenaya Therapeutics, Inc.

TNYA · Biological Products, (No Diagnostic Substances)

Cannabis Bioscience International Holdings, Inc.

CBIH · Services-Commercial Physical & Biological Research

Coya Therapeutics, Inc.

COYA · Pharmaceutical Preparations

IQVIA HOLDINGS INC.

IQV · Services-Commercial Physical & Biological Research

Lexaria Bioscience Corp.

LEXX · Pharmaceutical Preparations

: 28.4.2026